Export 3 results:
Author Title Type [ Year(Asc)]
Filters: Author is Rubinstein, L  [Clear All Filters]
2010
L. Seymour, Ivy, S., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M., Le Blanc, M., Stewart, D., Crowley, J., Groshen, S., Humphrey, J., West, P., and Berry, D., “The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee”, Clin Cancer Res, vol. 16, pp. 1764-1769, 2010.
2006
H. X. Chen, Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., and Kaplan, R. S., “Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients with Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301”, J Clin Oncol, vol. 24, pp. 3354-3360, 2006.
1999
M. A. Smith, Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., and Vena, D., “Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.”, J Clin Oncol, vol. 17, no. 2, pp. 569-77, 1999.